Apostream to isolate circulating tumor cells (CTC) from castration-resistant prostate cancer patients (CRPC) that express androgen receptor variant 7 (AR-V7) associated with resistance to AR-targeting drugs.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e23025-e23025
Author(s):  
Darren W. Davis ◽  
Asifa Haider ◽  
Valerie Pierron ◽  
Fabien Schmidlin
Sign in / Sign up

Export Citation Format

Share Document